For almost two decades, ICH Q2(R1) was the only reference point for validating analytical methods.
That changed in late 2023. ICH Q2(R2) analytical method validation guidance was finalized alongside ICH Q14, and it changes how validation works.
For sponsors, this raises an immediate question. If your CDMO validated a method years ago under the old rules, is it still defensible?
Why ICH Q2(R1) Needed Replacing
Q2(R1) treated validation as a single event. You ran the studies once, generated a report, and filed it.
That model had real gaps:
• It did not link validation to how the method was developed
• It offered almost no guidance on managing a method over its lifetime
• It barely addressed modern techniques like NMR or ICP-MS
• It left statistical reporting loosely defined, often just mean and %RSD
ICH responded by splitting the topic in two: a new ICH Q14 guideline for analytical procedure development, and a fully revised Q2(R2) focused on validation itself.
The Core Shift: A Lifecycle Approach
The biggest change in ICH Q2(R2) analytical method validation is philosophical.
Validation is no longer a one-time checkbox. It is treated as an ongoing process across the method’s life.
This lifecycle approach validation model includes:
• Continuous performance monitoring after initial validation
• Formal handling of revalidation when something changes
• Co-validation, where multi-site data demonstrates predefined performance criteria are met
• Platform analytical procedures, applying a validated method to new products with reduced revalidation burden
• Formal transfer protocols with predefined acceptance criteria and statistical comparison plans
This mirrors how ICH already treats manufacturing processes under Q12. Methods are now managed the same way.
Alignment With ICH Q14
Q2(R2) was never meant to stand alone. It works alongside ICH Q14, which governs how analytical procedures are developed.
The logic connects directly:
• Q14 defines the Analytical Target Profile and the science behind method design
• Q2(R2) defines how that method’s performance gets verified
• Together they form one continuous record from development through validation
A method built under Q14 principles, with documented development data and a defined operating range, is far easier to validate and defend under Q2(R2) than one with no development paper trail.
What Changed in the Statistics
This is where the revision gets technical. Under the old guideline, accuracy and precision were typically reported as a mean and percent RSD. Q2(R2) pushes toward confidence interval validation instead.
• Point estimates for accuracy and precision should carry an appropriate confidence interval, not just a single number
• A combined criteria approach is now permitted, evaluating accuracy and precision together rather than as separate pass/fail checks
• Multivariate procedures get their own statistical treatment, comparing prediction error to calibration error for quantitative methods
A 2024 ISPE survey found real friction here. More than three quarters of respondents had concerns about the confidence interval requirement, roughly 40% worried about needing more replicates, and about a fifth were unsure how to set acceptance limits.
What Sponsors Must Verify From Their CDMO
If your CDMO’s methods were validated under Q2(R1), here is what actually needs checking.
1. Ask whether raw validation data still exists. Confidence intervals can sometimes be recalculated from old accuracy and precision data without rerunning experiments, if raw replicate data was retained.
2. Check the method transfer protocol. Q2(R2) expects a predefined protocol with acceptance criteria and a statistical comparison method. Many older transfer packages were informal.
3. Ask if platform methods are being used. If your CDMO applies a method across multiple products, ask whether co-validation data supports that use, rather than treating each application as a fresh validation.
4. Confirm documentation links development to validation. Regulators increasingly expect a continuous record, not a validation report disconnected from how the method was built.
5. Check non-chromatographic method capability. If your program needs NMR, ICP-MS, or NIR, confirm your CDMO’s statistical approach matches the expanded scope, not legacy chromatography-only assumptions.
How LAXAI Approaches This
LAXAI’s analytical development team builds method development and validation as one connected process, not two disconnected exercises.
Validation reports document the statistical basis for accuracy and precision, including confidence intervals where applicable, and transfer packages include predefined protocols rather than informal comparisons.
For programs carrying methods developed before the Q2(R2) transition, LAXAI’s team assesses what gap-filling work is genuinely needed instead of defaulting to full revalidation by habit.
Talk to LAXAI’s analytical development team at bd@laxai.com
FAQs
When did ICH Q2(R2) take effect?
The ICH Assembly adopted Q2(R2) and Q14 in November 2023. EMA set 14 June 2024 as the effective date, and FDA announced final guidances in March 2024.
Does a method validated under Q2(R1) need revalidation under Q2(R2)?
Not automatically. Q2(R2) supports science and risk-based justification for whether revalidation is needed, based on which performance characteristics are affected. A gap assessment is more practical than blanket revalidation.
What is a platform analytical procedure?
A previously validated method used across multiple related products, supported by data showing it performs consistently. Q2(R2) formally recognizes this concept to reduce redundant revalidation.
Why are confidence intervals now expected for accuracy and precision?
A confidence interval gives a more statistically robust picture of method performance than a single mean and %RSD value, and it directly addresses how variability and sample size affect confidence in the result.
